Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis

APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is significantly shorter in mice than in humans (1.4 to 2.75...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yanan, Lee, Min Hee, Paderu, Padmaja, Lee, Annie, Jimenez-Ortigosa, Cristina, Park, Steven, Mansbach, Robert S., Shaw, Karen Joy, Perlin, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153843/
https://www.ncbi.nlm.nih.gov/pubmed/30012766
http://dx.doi.org/10.1128/AAC.00425-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153843/
https://www.ncbi.nlm.nih.gov/pubmed/30012766
http://dx.doi.org/10.1128/AAC.00425-18

Ejemplares similares